EMA Authorised: Xyrem (sodium oxybate) — UCB Pharma Ltd

View source ↗

Summary

The European Medicines Agency authorised Xyrem (sodium oxybate) for cataplexy and narcolepsy. The marketing authorization holder is UCB Pharma Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataplexy
• Narcolepsy

Drugs mentioned

• Xyrem (Sodium Oxybate)

Snippet

Status: Authorised. Therapeutic area: Cataplexy;Narcolepsy. MAH: UCB Pharma Ltd. Decision date: 12/05/2025